Dr. reddy's laboratories canada announces the launch of reddy-lenalidomide, one of the first generic medications of its kind for the canadian market

Hyderabad, india & mississauga, ontario--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”) today announced that reddy-lenalidomide, a generic equivalent to revlimid® (lenalidomide) capsules, is approved by health canada and has been launched in the canadian market. reddy-lenalidomide is one of the first generic medications of its kind to launch in canada. “our launch of reddy
RDY Ratings Summary
RDY Quant Ranking